Conventus Flower Orthopedics, a privately held medical technology company based in Horsham, Pennsylvania, has named Brad Niemann as chief executive officer.
Conventus Flower Orthopedics Names Brad Niemann CEO
1 min read Premium comments
Secondary#bradniemann#conventusflowerorthopedics
Niemann has over 20 years of experience in executive management roles in the medical device industry. He joins Conventus Flower Orthopedics from Stamford, Connecticut-based WellAir Solutions where he spent nearly four years with the indoor air solutions company as executive vice president.
Prior to WellAir, Niemann held multiple leadership roles with Lewisville, Texas-based Orthofix Medical Inc., a global medical device company. In his most recent role at Orthofix, he served as president of Orthofix Spine. Prior to that promotion, he was president of BioStem.
Niemann also held a number of positions with Lewisville, Texas-based DJO Global before his time with Orthofix. His roles included senior vice president and general manager. As senior vice president of recovery sciences he “led their commercial team and aided in M&A efforts.”
Conventus Flower Orthopedics Chairman of the Board Rick Epstein commented, “The Board of Directors and Deerfield Management are pleased to have an incredible leader like Brad [Niemann] join Conventus Flower Orthopedics.”
Epstein continued, “His proven leadership, strong operational expertise, and extensive experience managing significant growth will be invaluable to the Company as we continue to launch new, highly differentiated products.”
The Conventus Flower Orthopedics portfolio of products includes Ready-for-Surgery™ foot and ankle surgical solutions. Last year the company, according to its LinkedIn, launched its Flex-Thread™ distal fibula intramedullary nail system, a solution for the treatment of osteotomies and ankle fractures.
Niemann commented, “I am thrilled to join the Conventus Flower Orthopedics team.”
Niemann continued, “There is an incredible energy among the Conventus Flower leadership team, and I am excited and honored to continue the momentum the team has established in the market. The Company’s core products, innovative new products within the Flex-Thread™ portfolio, and the expanding pipeline set the organization up for continued growth.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.